Mirum Pharmaceuticals, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Mirum Pharmaceuticals, Inc. | MIRM - NASDAQ |
$14.00-$16.00 | $15.00 | $13.00 | 5 million | 7/18/2019 |
| Citigroup, Evercore ISI, Guggenheim Securities | ||||||
Co-Manager(s): Raymond James, Roth Capital | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-06-21 Terms Added 2019-07-08 | ||||||
Mirum Pharmaceuticals, Inc. Quote & Chart - Click for current quote - MIRM
IPO Boutique aggregates information on public companies and private companies, such as "MIRM" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Mirum Pharmaceuticals, Inc. (adapted from Mirum Pharmaceuticals, Inc. prospectus):
They are a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "MIRM" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.